OncoMatch/Clinical Trials/NCT02543710
Biomarker Guided Treatment in Gynaecological Cancer
Is NCT02543710 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer for endometrial cancer.
Treatment: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer — MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already identified and promising molecular biomarkers, to promote individualisation of treatment for patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have shown to be interesting in retrospective analysis of our large prospectively collected MoMaTEC1 series. Part 1: Performance of a phase 4 implementation trial for optimised stratification of surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy guided by validated biomarkers. Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian cancer. In this study stathmin will be used as integrated biomarker.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: STMN1 expression (stathmin level in the tumour recurrence)
Technical possibility to obtain a new tissue biopsy to determine stathmin level in the tumour recurrence.
Prior therapy
Must have received: taxane (paclitaxel) — third or fourth line treatment
offered weekly taxane (paclitaxel) treatment. This will often be a third or fourth line treatment, i.e. patients with advanced disease.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify